Projects
Medical Sales Representative Learnership
Background
The learnership for Medical Sales Representatives (MSRs) was commenced in 2000
with the intention of developing a pool of MSRs from designated groups. A pilot
learnership was commenced in April 2003 with 60 learners from a biology
bridging programme. 53 learners complete the programme. As a result of problems
encountered with this project the development of MSRs was stopped.
During 2005 the Pharmaceutical Chamber investigated the matter as stakeholders
in the Pharmaceutical and FMCG Chamber consider MSR to be a scarce skill. It
also offers an opportunity to effect transformation at higher levels within the
pharmaceutical industry. Work was initiated to identify and address the
problems related to the development of MSRs but this is not progressing at an
acceptable rate. The problems and proposed solutions are stated below.
Problem Statement
- Act 90 of 1997 Medicines and Related Substances Control Act
– Amendment Section 18 requires that the Minister of Health prescribes a
Code of Marketing Practice prescribing the marketing of medicines by the
industry.
- In terms of Section 16 of the Code representatives must be assessed against
nationally recognised standards and those representatives with less than 2
years of industry experience are required to complete a full Medical Sales
Representative Qualification.
- Difficulties were experienced with the pilot learnership carried out against
qualification no 17099.
- The issue of National Certificated to learners who completed the pilot
programme has not been possible as the providers were not accredited.
- Accreditation was not carried out by the CHIETA ETQA as the South African
Pharmacy Council (SAPC) claimed the right to accredit this qualification and
SAQA recognised the SAPC as the ETQA for this qualification.
- SAPC has not carried out accreditation because of a lack of Memorandum of
Understanding between SAPC and the Higher Education Committee and the need to
source expertise to address the ‘sales’ component of the
qualification.
- SAPC does not recognise the registered qualification as acceptable for the
registration of MSRs.
- Learners on the pilot programme were not accepted into the industry as
envisaged. Reasons for this include the lack of drivers licences and a lack of
prior learning (typically prospective MSRs have a related tertiary
qualification and experience before commencing training)
- It is accepted that the current qualification is sub-standard but that is
‘legal’ in terms of registration with SAQA.
- SAPC has not been proactive in developing the Scope of Practice required for
MSRs or a new qualification for MSRs.
Work towards solving the problem
- The Joint Stakeholder Forum supported the recommendation by the Pharmaceutical
& FMCG Chamber to recognise the MSR as scarce skills (November 2005).
- Representatives of the Chamber supported by LAAPI met with representatives of
the SAPC and SAQA in January 2006 to consider the problems and solutions.
(Minutes are attached below).
- Response from the SAPC meeting of 10/11 May 2006 arising from this meeting and
requests for a way to address the issues, was received by the Chamber
Specialist. (Letter dd 24 May 2006).
- The matter was addressed by the EDTQA Division at a meeting attended by chamber
and industry representatives on 25th May 2006. At this meeting it was
recommended that the CHIETA ETQA request SAQA to allow it to accredit the
provider against the current qualification. SAPC would be invited to partake in
this work. Assuming a positive result from this accreditation, the SAPC would
be expected to issue certificates to learners from the pilot project who were
found competent. Alternatively the SAPC would be expected to specify what must
be done before these certificates can be issued.
- Representatives of the EDTQA Division and SAPC met with the Directorate Quality
Assurance of SAQA on the 8th of June 2006 (note attached below). At this
meeting the following was highlighted –
- That SAPC was very strongly requested to conduct a ‘sample
verification’ and award certification against the existing qualification
(17099) and upload the learner information on the NLRD.
- It is accepted that the Current Qualification may not be compliant with the
scope of conduct to be developed by the SAPC. Learners will be informed of this
and that they will probably require ‘top-up’ learning to comply
with future registration requirements.
- The current qualification will re-registered until a new qualification for
Medical Sales Representative is registered by the Pharmaceutical SGB.
- SAPC must quality assure the qualification assigned to them.
- SAPC need to develop a code of conduct prior to writing the qualification. The
Pharmaceutical SGB should invite the industry to assist in the writing process.
- CHIETA may consider requests for assistance with standard generation from the
SAPC if a proposal is received.
|